Inhibitec Antibodies, S.L. Cantabrian biotechnology company, spin-off of the CSIC and University of Cantabria, has developed a monoclonal antibody for a new therapeutic target. Last week, it was in Cambridge, within the Idea Spark Program designed by MIT and SODERCAN.
A significant number of psoriatic patients with severe disease do not respond to existing therapies. A key molecule involved its pathogenic is BAMBI and its inhibition with our specific mAbs (BI0137) prevents skins and articular lesions in preclinical experimental models of psoriasis.
-
Video interview in Popular TV Cantabria: https://www.youtube.com/watch?v=Vd88eKx-MPk
-
Video reportUniversidad de Cantabria: https://www.youtube.com/watch?v=lYaL7_a7NDc
-
El Massachusetts Instituteof Technology(MIT) selecciona a dos startup cántabras para participar en el Programa Idea2 Global impulsado por SODERCAN.
-
InhibitecAnticuerpos, empresa surgida del IBBTEC, busca un fármaco para curar la psoriasis severa (el diario Montañés 6-07-2019)
https://www.eldiariomontanes.es/cantabria/inhibitec-anticuerpos-empresa-20190705190326-nt.html